Next Generation Propellant Technology for Pharmaceutical MDI Applications
Challenge from the Client
A global manufacturer and distributor of bulk propellant materials, infrastructure products and services develops the next generation of fluorine-based novel product propellant technology for pharmaceutical metered dose inhalation (MDI) applications.
This project extended our clients current business scope of operation in line with their integration strategy of delivering products and services for MDI by:
- Providing CGMP development, pre-clinical sample materials supply and testing service to organization’s seeking to bring MDI products to market.
- Providing contract manufacturing capability to organisations seeking to supply clinical and product launch materials to market based on novel propellant product technology.
- Providing contract manufacturing capability to organisations seeking to outsource or supplement their MDI product manufacturing and distribution capabilities.
Our Approach & Solution
By taking a modular and “plug and play” approach to process design, full production operation for the commercial line will increase to 500 litres bulk manufacturing scale producing 40,000 aerosols per batch.
The manufacturing process was based on flammable propellants that required ATEX zoned areas. Both the manufacturing formulation and filling equipment were located in controlled operating environments having a minimum cleanroom classification equivalent to EU GMP classified Grade D, and ATEX ratings of Zone 1 for the manufacturing and Zone 2 for the filling room. Both manufacturing and filling rooms had pressure-relieving and pressure-resistant building construction to minimize the damage caused by the potential for combustion explosions whilst maintaining full cleanroom environments. The facility design and site master planning allowed for multiple MDI line additions as business grows over time without impacting current manufacturing/filling operations.
An external service yard with hazardous bulk material storage area for bulk API propellant, solvent intermediates and solvent recovery systems was connected by overhead pipe bridges to the new facility.
The Health Hazard Categories for the active ingredients range from OEB2 to OEB4. Exposure control strategies are commensurate with exposure risk. This is accomplished through guidance providing appropriate risk-based exposure control strategies for the processing equipment.
Initially, UK MHRA licences will be obtained, closely followed by US FDA and other significant worldwide equivalents.
IPS provided technical expertise with their understanding of site master planning new facilities and infrastructure as well as define MDI process technology, supporting infrastructure and environmental design requirements.
The Results
The initial design concepts and 3D visualisations of both process and facility enabled the client to leverage new commercial opportunities within the MDI market sector and in parallel develop their business case and capital investment required to progress the project internally.
Related Molecules
Antibody Drug Conjugation Commercial Manufacturing
Read MoreApplied first class design tools and industry specific experiences to develop a greenfield site for commercial ADC manufacturing.
Mobile Modular Vaccine Facility
Read MoreDeliver a modular vaccine facility capable of being relocated anywhere in the world with minimal host facility requirements.
Delivering a New Building with Two Project Teams
Read MoreProvided a client and building tenant with construction management services for the interior fit-out of a new 50,000sf pharmaceutical testing facility while a separate vendor constructs the core & shell for the landlord.
Annex 1 - The Brave New World of Aseptic Regulatory Compliance
Read MoreAfter six years in review, the final emergence of Annex 1 in August 2022 has either been a consolidation of accepted practice and wisdom, or a rude awakening for many!
Clinical Aseptic Spray Drying Facility Project
Read MoreIPS utilized the Inceptioneering process and expertise in aseptic spray drying technology for manufacturing APIs for formulation and filling.
Single-Use Mammalian Cell Culture Facility - Vial to Vial
Read MoreOur challenge was to design a biologics manufacturing launch facility within an existing shell & office building.
Replacement Powder Mill for Pharmaceutical Client
Read MoreAfter a previous remediation attempts from other consultants failed, IPS was brought in to solve our client’s excess temperature problems in their new milling equipment.
Potent Processing on Antiquated Equipment
Read MoreIPS experts provided the latest technical solutions to retrofit a facility to improve manufacturing processes.
Modular Design, Construction and Installation of QC Labs
Read MoreA copy/paste modular build from the UK to Spain that overcame hurdles from the UK’s decision to leave the European Union.
Design of an Award-Winning, Fully Integrated Dual Sterile Filtration Unit, With In-situ Integrity Testing and Elimination of Contamination Routes
Read MoreIPS experts designed a filter skid system to eliminate contamination risks related to manual operations.
Innovative Commercial-Scale Parenteral Fill/Finish Facility
Read MoreUsing Facility of the Future design principles, IPS designed a world-class, flexible, 490,000sf. facility.
Fast-Track Project Delivery Model
Read MoreA vaccine manufacturer and distributor needed IPS’ expertise to meet an aggressive timeline for expansion of their production facility.
Detailed Process Piping
Read MoreSupporting a client’s dynamic business requirements to produce a near-fabrication-level model to reduce schedule time.
3D Modelling and Laser Scanning
Read More3D laser scanning used to coordinate and design a new PTW generation skid and pipework connections within an existing operating facility.
Advanced Design for New High Output Medical Device Campus
Read MoreThe new world-class campus is designed and master planned with flexibility at its core. The master plan supports the initial construction of the Phase I scope on a 48-acre plot
Medical Device Know-How
Read MoreFrom strategic master planning to detailed construction documentation, IPS developed a comprehensive plan for a large-scale expansion.
